Short Interest in RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Decreases By 40.5%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 201 shares, a decrease of 40.5% from the June 30th total of 338 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 338 shares, the short-interest ratio is currently 0.6 days.

RCN Pareto Strategic Allocation ETF Stock Performance

Shares of PRTO stock traded down $0.07 during trading on Friday, reaching $27.12. The company had a trading volume of 340 shares. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.16. The company has a market capitalization of $601.49 million, a price-to-earnings ratio of -28.25 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.